THE COVID-19 PANDEMIC in 2020 was an unexpected boon for India’s drugs and pharmaceuticals industry: foreign direct investment (FDI) shot up by 188 per cent to $1.5 billion in 202021 from $517 million in 2019-20.
The FDI came into India’s manufacturing prowess in vaccines. The next year, FDI slipped by 5 per cent but surged by 46 per cent in 2022-23.
All this is good news for India’s presidency of the G20 bloc. The G20 presidency, say industry experts, has given centre stage to India, reaffirming its position as a leading player in healthcare and pharmaceuticals.
And it is not just vaccines: over the past five years, top multinationals have been injecting FDI into India’s drugs and pharmaceuticals sector. The Indian pharma sector is the world’s largest provider of generic drugs, with 20 per cent of global exports in terms of volume, according to India Brand Equity Foundation (IBEF), the branding and communications body for trade and exports under the commerce and industry ministry.
Now it’s up to India’s corporates to grab big roles in the world pharma play.
Satish Reddy, Chairman of Dr. Reddy’s Laboratories Ltd, India’s second-largest pharma major by gross sales, says, “India’s G20 presidency plays a crucial role in strengthening the nation’s identity as the world’s pharma hub.”
The G20, a forum of the world’s advanced economies—including the European Union— and developing countries, currently has 23 members, which account for 85 per cent of the world’s GDP. It meets annually to discuss global issues.
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
"Focus on the challenge of each customer"
SHASHANK KUMAR MD & CO-FOUNDER I RAZORPAY Razorpay is India's first full-stack financial solutions company
PEDAL ON THE FUTURE
THE MG WINDSOR EV, WITH ITS FUTURISTIC AND MINIMALIST DESIGN, COMBINES THE BEST OF BOTH WORLDS-COMFORT AND TECHNOLOGY
BREATHE EASY
Whether you're battling allergies, looking to remove pollutants, or simply want to breathe easier, the right air purifier can make a difference
The Taste of India in a Glass
FROM ROYAL LIQUEURS TO DISTILLED MAHUA, INDIAN HERITAGE ALCOHOLIC BEVERAGES ARE HAVING THEIR DAY IN THE SUN
LOOK BEFORE YOU LEAP
IN 2025, INVESTORS WILL NEED TO FACTOR IN VOLATILITY ACROSS ASSET CLASSES
MISSING ADVISORS
INDIA HAS JUST ONE INVESTMENT ADVISOR FOR NEARLY EVERY 200,000 INVESTORS. AT A TIME WHEN RETAIL PARTICIPATION IN THE STOCK MARKETS IS BOOMING, THIS ASSUMES SIGNIFICANCE
TURNING A CORNER
SHARED ELECTRIC MOBILITY START-UP YULU'S SHIFT TO SERVICING THE QUICK COMMERCE SECTOR IS HELPING IT GROW FAST. IT IS NOW FOCUSSING ON IMPROVING ROAD SAFETY FEATURES AS IT TURNS EBITDA POSITIVE
REALITY CHECK
INDIAN STOCK MARKETS PLUNGED BEGINNING OCTOBER FOR A HOST OF REASONS, INCLUDING A FALL IN FII OWNERSHIP. HOW DEEP WILL THE CORRECTION BE?
TRUMP'S TRADE TANGO
The return of Donald Trump as the 47th President of the US has put the global economy on edge. India, too, is unlikely to remain unaffected. How will policymakers meet this latest challenge?
"The essence of the Trump administration will be transactional”
Global investor, analyst, and best-selling author Ruchir Sharma decodes why Donald Trump won the elections, what India should do, the risks, and more